Similar Articles |
|
The Motley Fool February 3, 2011 Brian Orelli |
Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes. |
The Motley Fool July 23, 2008 Brian Orelli |
Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down. |
The Motley Fool April 23, 2008 Brian Orelli |
Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up. |
The Motley Fool July 29, 2011 Brian Orelli |
Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last? |
The Motley Fool April 21, 2009 Brian Orelli |
Boston Scientific Rebuilds Whether the company is a value or a value trap depends on how well the rebuilding goes this year. |
The Motley Fool January 29, 2009 Brian Orelli |
No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed. |
The Motley Fool December 5, 2005 Stephen D. Simpson |
Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note. |
The Motley Fool February 5, 2008 Brian Orelli |
Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter. |
The Motley Fool October 20, 2009 Robert Steyer |
The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it. |
The Motley Fool October 13, 2008 Brian Orelli |
Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier. |
The Motley Fool June 26, 2009 Brian Orelli |
Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss. |
The Motley Fool April 24, 2007 Ryan Fuhrmann |
Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock. |
The Motley Fool July 23, 2007 Ryan Fuhrmann |
Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note. |
The Motley Fool October 23, 2008 Brian Orelli |
Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter. |
The Motley Fool July 21, 2010 Brian Orelli |
Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now. |
The Motley Fool May 29, 2008 Brian Orelli |
Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific. |
The Motley Fool February 1, 2010 Brian Orelli |
Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost. |
The Motley Fool April 9, 2010 Brian Orelli |
Is Boston Scientific Turning It Around? Selling off a pair of units could help. |
The Motley Fool February 5, 2007 Ryan Fuhrmann |
Boston Scientific's Unscientific Outlook There's still uncertainty as the med-tech company blends an acquisition and deals with controversy. Investors, take note. |
The Motley Fool May 28, 2009 Brian Orelli |
Boston Scientific Back in an Atomic Way Can its tiny stent save the day? |
The Motley Fool November 24, 2009 Brian Orelli |
52-Week Highs! What's Going On? Even with its recent leap, this stock may belong in your portfolio. Medtronic raised earnings guidance today after a fairly strong quarter, and the stock is hitting new 52-week highs. |
The Motley Fool September 14, 2011 Brian Orelli |
How to Muck Up a Turnaround in 12 and a Half Months Boston Scientific's choice for a new CEO has the potential to really muck up its recovery even further -- if that's even possible. |
The Motley Fool February 17, 2009 Brian Orelli |
Investors Heart Medtronic The leaner company is more lovable. |
The Motley Fool August 18, 2008 Brian Orelli |
Foolish Forecast: Taking Medtronic to Heart In advance of earnings analysts expect Medtronic, with another medical device approval, to boost revenues 17%. |
The Motley Fool February 7, 2006 Stephen D. Simpson |
Boston Scientific's Big Task The company won the battle for Guidant, but the hard work hasn't even begun. Value is value, and if Boston Scientific proves it can handle the considerable challenges ahead, this could ultimately be a very interesting stock again. |
The Motley Fool April 19, 2005 Stephen D. Simpson |
Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good. |
The Motley Fool January 11, 2008 Brian Orelli |
Boston Scientific Lives Below Its Means Cost-cutting efforts should help turn the medical-device making company around in 2008. |
The Motley Fool May 14, 2008 Brian Orelli |
Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial. |
The Motley Fool May 25, 2010 Brian Orelli |
Medtronic Gets Tossed Out With the Bathwater A bad day to report good news. |
The Motley Fool September 26, 2005 Stephen D. Simpson |
Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors? |
The Motley Fool July 31, 2006 Stephen D. Simpson |
Can Boston Scientific Get It Right? To boost investor confidence, management must first prove itself. |
The Motley Fool August 12, 2010 Brian Orelli |
Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later. |
The Motley Fool November 9, 2009 Brian Orelli |
Guidant: The Gift That Keeps on Giving And not in the good way. Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant. |
The Motley Fool August 20, 2008 Brian Orelli |
Medtronic Muddles Through The medical device maker manages double-digit growth in a tough market. |
The Motley Fool July 7, 2008 Brian Orelli |
And Then There Were 4 The number of drug-eluting stent players in the U.S. doubles with the addition of Medtronic's Endeavor and Abbott Labs' Xience V. |
The Motley Fool May 28, 2004 W.D. Crotty |
Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability. |
The Motley Fool August 25, 2009 Brian Orelli |
Medtronic Takes the Road Less Traveled It looks like this medical devices company is healthy again. |
The Motley Fool September 30, 2009 Brian Orelli |
Boston Scientific Pays Up And Johnson & Johnson reaps the rewards. |
The Motley Fool May 27, 2004 Jeff Hwang |
Guidant's Stent Stumble Yesterday, Guidant said that a regulatory filing for marketing approval of its Champion stainless steel stent could be delayed up to six months due to "issues" that may result in "manufacturing process modifications and/or stent design changes." |
The Motley Fool October 14, 2005 Stephen D. Simpson |
Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is. |
The Motley Fool April 27, 2010 Brian Orelli |
Boston Scientific's "Challenging" Quarter Boston Scientific fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless. |
The Motley Fool January 6, 2005 Stephen D. Simpson |
Can Medtronic Still Quicken the Pulse? While increased competition looms for the medical device maker, a shareholder update looks to the past. |
The Motley Fool December 31, 2007 Brian Orelli |
Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed. |
The Motley Fool January 17, 2006 Stephen D. Simpson |
High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this. |
The Motley Fool September 29, 2010 Brian Orelli |
Boston Scientific: Strengths, Weaknesses, Opportunities, Threats One of the best ways to develop a picture of any company is with the SWOT analysis -- a look at a company's strengths, weaknesses, opportunities, and threats. Let's take a look at Boston Scientific in this light as it tries to turn itself around. |
The Motley Fool November 11, 2009 Jim Mueller |
This Company Is a Value Stock! Isn't It? A look at Boston Scientific leads to conflicting conclusions. |
The Motley Fool January 25, 2006 Stephen D. Simpson |
Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note. |
The Motley Fool February 24, 2004 Alyce Lomax |
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain? |
The Motley Fool August 6, 2004 Jeff Hwang |
Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share? |
The Motley Fool July 19, 2005 Stephen D. Simpson |
Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note. |